Lipid ligand-activated transcription factors regulating lipid storage and release in human macrophages

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1791, Issue 6, 2009, Pages 486-493

  Chinetti Gbaguidi, G ^a,b,c   Staels, B ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

Atherosclerosis; Cholesterol metabolism; Gene expression; Transcription factor

Indexed keywords

LIGAND; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROSCLEROTIC PLAQUE; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG EFFECT; DRUG MECHANISM; EFFUSION; FOAM CELL; HOMEOSTASIS; HUMAN; INFLAMMATION; LIPID STORAGE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION;

EID: 67349268534     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2009.01.009     Document Type: Review

References (121)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
2. Beaven S.W., and Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57 (2006) 313-329
3. Chinetti G., Griglio S., Antonucci M., Pineda Torra I., Delerive P., Majd Z., Fruchart J.C., Chapman J., Najib J., and Staels B. Activation of peroxisome proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273 (1998) 25573-25580
4. Blanquart C., Mansouri R., Paumelle R., Fruchart J.C., Staels B., and Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol. Endocrinol. 18 (2004) 1906-1918
5. Blanquart C., Mansouri R., Fruchart J.C., Staels B., and Glineur C. Different ways to regulate the PPARalpha stability. Biochem. Biophys. Res. Commun. 319 (2004) 663-670
6. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., and Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429 (2004) 771-776 (London)
7. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763 (London)
8. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., and Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 25 (2007) 57-70
9. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. PPARα negatively regulates the vascular wall inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
10. Delerive P., De Bosscher K., Vanden Berghe W., Fruchart J.C., Haegeman G., and Staels B. DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol. Endocrinol. 16 (2002) 1029-1039
11. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., Morel C.R., Subramanian V., Mukundan L., Eagle A.R., Vats D., Brombacher F., Ferrante A.W., and Chawla A. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 (2007) 1116-1120 (London)
12. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., Zawadski C., Jude B., Torpier G., Marx N., Staels B., and Chinetti-Gbaguidi G. PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6 (2007) 137-143
13. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6712-6717
14. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., and Glass C.K. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15 lipoxygenase. Nature 400 (1999) 378-382 (London)
15. Hevener A.L., Olefsky J.M., Reichart D., Nguyen M.T., Bandyopadyhay G., Leung H.Y., Watt M.J., Benner C., Febbraio M.A., Nguyen A.K., Folian B., Subramaniam S., Gonzalez F.J., Glass C.K., and Ricote M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117 (2007) 1658-1669
16. Marathe C., Bradley M.N., Hong C., Chao L., Wilpitz D., Salazar J., and Tontonoz P. Preserved glucose tolerance in high fat diet-fed C57BL/6 mice transplanted with PPARgamma-/-, PPARdelta-/-, PPARgamma delta-/- or LXRalpha beta-/- bone marrow. J. Lipid Res. 50 (2009) 214-224
17. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., and Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
18. Kang K., Reilly S.M., Karabacak V., Gangl M.R., Fitzgerald K., Hatano B., and Lee C.H. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7 (2008) 485-495
19. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., Vats D., Morel C.R., Goforth M.H., Subramanian V., Mukundan L., Ferrante A.W., and Chawla A. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab. 7 (2008) 496-507
20. Isseman I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650 (London)
21. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPARα, β and γ in the adult rat. Endocrinology 137 (1995) 354-366
22. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
23. Mansen A., Guardiola-Diaz H., Rafter J., Branting C., and Gustafsson J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 222 (1996) 844-851
24. Braissant O., and Wahli W. Differential expression of peroxisome proliferator-activated receptor-α, -β and -γ during rat embryonic development. Endocrinology 139 (1998) 2748-2754
25. Inoue I., Shino K., Noji S., Awata T., and Katayama S. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246 (1998) 370-374
26. Marx N., Bourcier T., Sukhova G., Libby P., and Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-I expression. Arterioscler. Throm. Vasc. Biol. 19 (1999) 5465-5551
27. Marx N., Sukhova G., Collins T., Libby P., and Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
28. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Duriez P., and Staels B. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway. Circ.Res. 85 (1999) 394-402
29. Xin X., Yang S., Kowalski J., and Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274 (1999) 9116-9121
30. Staels B., Koenig W., Habib A., Merval R., Lebret M., Pineda-Torra I., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393 (1998) 790-793 (London)
31. Marx N., Schönbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ.Res. 83 (1999) 1097-1103
32. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., and Glass C.K. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7614-7619
33. Ricote M., Li A.C., Willsson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82 (London)
34. Chinetti G., Gbaguidi G.F., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.C., Tedgui A., Najib-Fruchart J., and Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 101 (2000) 2411-2417
35. Vosper H., Patel L., Graham T.L., Khoudoli G.A., Hill A., Macphee C.H., Pinto I., Smith S.A., Suckling K.E., Wolf C.R., and Palmer C.N.A. The peroxisome proliferator-activated receptor promotes lipid accumulation in human macrophages. J. Biol. Chem. 276 (2001) 44258-44265
36. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARα-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43 (London)
37. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4318-4323
38. Forman B.M., Chen J., and Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4312-4317
39. Bensinger S.J., and Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 (2008) 470-477 (London)
40. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-D12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 (1995) 803-812
41. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 (1995) 813-819
42. Nagy L., Tontonoz P., Alvarez J.G.A., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93 (1998) 229-240
43. Delerive P., Furman C., Teissier E., Fruchart J.-C., Duriez P., and Staels B. Oxidized phospholipids activate PPARα in a phospholipase A2-dependant manner. FEBS Lett. 471 (2000) 34-38
44. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., and Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11693-11697
45. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
46. Sznaidman M.L., Haffner C.D., Maloney P.R., Fivush A., Chao E., Goreham D., Sierra M.L., LeGrumelec C., Xu H.E., Montana V.G., Lambert M.H., Willson T.M., Oliver Jr. W.R., and Sternbach D.D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521
47. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., and Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129 (2007) 723-733
48. Rieck M., Meissner W., Ries S., Muller-Brusselbach S., and Muller R. Ligand-mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid. Mol. Pharmacol. 74 (2008) 1269-1277
49. Duez H., Lefebvre B., Poulain P., Torra I.P., Percevault F., Luc G., Peters J.M., Gonzalez F.J., Gineste R., Helleboid S., Dzavik V., Fruchart J.C., Fievet C., Lefebvre P., and Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 585-591
50. Gross B., and Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21 (2007) 687-710
51. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., and Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9 (1995) 1033-1045
52. Ahuja H.S., Szanto A., Nagy L., and Davies P.J. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul Homeost Agents 17 (2003) 29-45
53. Wagner B.L., Valledor A.F., Shao G., Daige C.L., Bischoff E.D., Petrowski M., Jepsen K., Baek S.H., Heyman R.A., Rosenfeld M.G., Schulman I.G., and Glass C.K. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell Biol. 23 (2003) 5780-5789
54. Terasaka N., Hiroshima A., Ariga A., Honzumi S., Koieyama T., Inaba T., and Fujiwara T. Liver X receptor agonists inhibit tissue factor expression in macrophages. Febs J. 272 (2005) 1546-1556
55. Ogawa D., Stone J.F., Takata Y., Blaschke F., Chu V.H., Towler D.A., Law R.E., Hsueh W.A., and Bruemmer D. Liver x receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 96 (2005) e59-e67
56. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003) 213-219
57. Castrillo A., Joseph S.B., Marathe C., Mangelsdorf D.J., and Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278 (2003) 10443-10449
58. Chen M., Bradley M.N., Beaven S.W., and Tontonoz P. Phosphorylation of the liver X receptors. FEBS Lett. 580 (2006) 4835-4841
59. Yamamoto T., Shimano H., Inoue N., Nakagawa Y., Matsuzaka T., Takahashi A., Yahagi N., Sone H., Suzuki H., Toyoshima H., and Yamada N. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J. Biol. Chem. 282 (2007) 11687-11695
60. Delvecchio C.J., and Capone J.P. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol. 197 (2008) 121-130
61. Torra I.P., Ismaili N., Feig J.E., Xu C.F., Cavasotto C., Pancratov R., Rogatsky I., Neubert T.A., Fisher E.A., and Garabedian M.J. Phosphorylation of liver X receptor alpha selectively regulates target gene expression in macrophages. Mol. Cell Biol. 28 (2008) 2626-2636
62. Li X., Zhang S., Blander G., Tse J.G., Krieger M., and Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell. 28 (2007) 91-106
63. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., and Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383 (1996) 728-731 (London)
64. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., and Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad Sci. U. S. A. 96 (1999) 266-271
65. Mitro N., Mak P.A., Vargas L., Godio C., Hampton E., Molteni V., Kreusch A., and Saez E. The nuclear receptor LXR is a glucose sensor. Nature 445 (2007) 219-223 (London)
66. Denechaud P.D., Bossard P., Lobaccaro J.M., Millatt L., Staels B., Girard J., and Postic C. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver,. J. Clin. Invest. 118 (2008) 956-964
67. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., and Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000) 2831-2838
68. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., Parks D.J., Wilson J.G., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., and Willson T.M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J Med Chem 45 (2002) 1963-1966
69. Albers M., Blume B., Schlueter T., Wright M.B., Kober I., Kremoser C., Deuschle U., and Koegl M. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 281 (2006) 4920-4930
70. Phelan C.A., Weaver J.M., Steger D.J., Joshi S., Maslany J.T., Collins J.L., Zuercher W.J., Willson T.M., Walker M., Jaye M., and Lazar M.A. Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment. Mol. Endocrinol. 22 (2008) 2241-2249
71. Houck K.A., Borchert K.M., Hepler C.D., Thomas J.S., Bramlett K.S., Michael L.F., and Burris T.P. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83 (2004) 184-187
72. Mitro N., Vargas L., Romeo R., Koder A., and Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581 (2007) 1721-1726
73. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., and Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14 (2000) 2819-2830
74. Cha J.Y., and Repa J.J. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282 (2007) 743-751
75. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., and Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277 (2002) 11019-11025
76. Chao E.Y., Caravella J.A., Watson M.A., Campobasso N., Ghisletti S., Billin A.N., Galardi C., Wang P., Laffitte B.A., Iannone M.A., Goodwin B.J., Nichols J.A., Parks D.J., Stewart E., Wiethe R.W., Williams S.P., Smallwood A., Pearce K.H., Glass C.K., Willson T.M., Zuercher W.J., and Collins J.L. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J. Med. Chem. 51 (2008) 5758-5765
77. Hu B., Quinet E., Unwalla R., Collini M., Jetter J., Dooley R., Andraka D., Nogle L., Savio D., Halpern A., Goos-Nilsson A., Wilhelmsson A., Nambi P., and Wrobel J. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity. Bioorg. Med. Chem. Lett. 18 (2008) 54-59
78. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., Lusis A.J., Collins A., Hseuh W.A., Collins J.L., Tangirala R.K., and Tontonoz P. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin Invest. 117 (2007) 2337-2346
79. de Villiers W.J., and Smart E.J. Macrophage scavenger receptors and foam cell formation. J. Leukoc. Biol. 66 (1999) 740-746
80. Yamashita S., Hirano K.I., Kuwasako T., Janabi M., Toyama Y., Ishigami M., and Sakai N. Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol. Cell Biochem. 299 (2007) 19-22
81. Gough P.J., Greaves D.R., Suzuki H., Hakkinen T., Hiltunen M.O., Turunen M., Ylä Herttuala S., Kodama T., and Gordon S. Analysis of macrophage scavenger receptor (SR-A) expression in human aortic atherosclerotic lesions. Arterioscler. Throm. Vasc. Biol. 19 (1999) 461-471
82. Herijgers N., de Winther M.P., Van Eck M., Havekes L.M., Hofker M.H., Hoogerbrugge P.M., and Van Berkel T.J. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J. Lipid Res. 41 (2000) 1402-1409
83. Tabas I. Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta 1529 (2000) 164-174
84. Garver W.S., and Heidenreich R.A. The Niemann-Pick C proteins and trafficking of cholesterol through the late endosomal/lysosomal system. Curr. Mol. Med. 2 (2002) 485-505
85. Watari H., Blanchette-Mackie E.J., Dwyer N.K., Glick J.M., Patel S., Neufeld E.B., Brady R.O., Pentchev P.G., and Strauss III J.F. Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 805-810
86. Gargalovic P., and Dory L. Caveolins and macrophage lipid metabolism. J. Lipid Res. 44 (2003) 11-21
87. Buhman K.F., Accad M., and Farese R.V. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim. Biophys. Acta 1529 (2000) 142-154
88. McGarry J.D., and Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244 (1997) 1-14
89. Jessup W., Gelissen I.C., Gaus K., and Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr. Opin. Lipidol. 17 (2006) 247-257
90. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809 (London)
91. Rigamonti E., Chinetti-Gbaguidi G., and Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1050-1059
92. Tontonoz P., Nagy L., Alvarez J., Thomazy V., and Evans R. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
93. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Med. 7 (2001) 48-52
94. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Pineda Torra I., Teissier E., Minnich A., Jaye M., Duverger N., Brewer B.H., Fruchart J.C., Clavey V., and Staels B. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med. 7 (2001) 53-58
95. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., and Freeman M.W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nature Med. 7 (2001) 41-47
96. Gbaguidi G.F., Chinetti G., Milosavljevic D., Teissier E., Chapman J., Olivecrona G., Fruchart J.C., Griglio S., Fruchart-Najib J., and Staels B. Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages. FEBS Lett. 512 (2002) 85-90
97. Zimmermann R., Panzenböck U., Wintersperger A., Levak-Frank S., Graier W., Glotter O., Kostner G.M., and Zechner R. Lipoprotein lipase mediates the uptake of glycated low density lipoprotein in fibroblasts, endothelial cells, and macrophages. Diabetes 50 (2001) 1643-1653
98. Li L., Beauchamp M.C., and Renier G. Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 165 (2002) 101-110
99. Haraguchi G., Kobayashi Y., Brown M.L., Tanaka A., Isobe M., Gianturco S.H., and Bradley W.A. PPARalpha and PPARgamma activators suppress the monocyte-macrophage apolipoprotein B48 receptor. J. Lipid Res. 44 (2003) 1224-1231
100. Rigamonti E., Helin L., Lestavel S., Mutka A.L., Lepore M., Fontaine C., Bouhlel M.A., Bultel S., Fruchart J.C., Ikonen E., Clavey V., Staels B., and Chinetti-Gbaguidi G. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 97 (2005) 682-689
101. Buono C., Li Y., Waldo S.W., and Kruth H.S. Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL. J. Lipid Res. 48 (2007) 2411-2418
102. Chinetti G., Lestavel S., Fruchart J.C., Clavey V., and Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ.Res. 92 (2003) 212-217
103. Argmann C.A., Sawyez C.G., McNeil C.J., Hegele R.A., and Huff M.W. Activation of peroxisome proliferator-activated receptor gamma and retinoid x receptor results in net depletion of cellular cholesteryl esters in macrophages exposed to oxidized lipoproteins. Arterioscler. Throm. Vasc. Biol. 23 (2003) 475-482
104. Ghosh S., and Natarajan R. Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem. Biophys. Res. Commun. 284 (2001) 1065-1070
105. Iida K.T., Kawakami Y., Suzuki H., Sone H., Shimano H., Toyoshima H., Okuda Y., and Yamada N. PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 520 (2002) 177-181
106. Larigauderie G., Cuaz-Perolin C., Younes A.B., Furman C., Lasselin C., Copin C., Jaye M., Fruchart J.C., and Rouis M. Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation. FEBS J. 273 (2006) 3498-3510
107. Larigauderie G., Furman C., Jaye M., Lasselin C., Copin C., Fruchart J.C., Castro G., and Rouis M. Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 504-510
108. Chinetti-Gbaguidi G., Rigamonti E., Helin L., Mutka A.L., Lepore M., Fruchart J.C., Clavey V., Ikonen E., Lestavel S., and Staels B. Peroxisome proliferator-activated receptor {alpha} controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 46 (2005) 2717-2725
109. Llaverias G., Vazquez-Carrera M., Sanchez R.M., Noe V., Ciudad C.J., Laguna J.C., and Alegret M. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J. Lipid Res. 45 (2004) 2015-2024
110. Smart E.J., Ying Y., Donzell W.C., and Anderson R.G. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J. Biol. Chem. 271 (1996) 29427-29435
111. Chawla A., Boisver W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., and Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7 (2001) 161-171
112. Akiyama T.E., Sakai S., Lambert G., Nicol C.J., Matsusue K., Pimprale S., Lee Y.H., Ricote M., Glass C.K., Brewer Jr. H.B., and Gonzalez F.J. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22 (2002) 2607-2619
113. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114 (2004) 1564-1576
114. Oliver W.R.J., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. (2001) 5306-5311
115. Quinn C.M., Jessup W., Wong J., Kritharides L., and Brown A.J. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARgamma ligands. Biochem. J. 385 (2005) 823-830
116. Costet P., Luo Y., Wang N., and Tall A.R. Sterol-dependent transactivation of the human ABC1 promoter by LXR/RXR. J. Biol. Chem. 275 (2000) 28240-28245
117. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., and Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRalpha [In Process Citation]. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12097-12102
118. Engel T., Lorkowski S., Lueken A., Rust S., Schluter B., Berger G., Cullen P., and Assmann G. The human ABCG4 gene is regulated by oxysterols and retinoids in monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 288 (2001) 483-488
119. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., and Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 507-512
120. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., Tontonoz P., and Edwards P.A. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277 (2002) 31900-31908
121. Laffitte B.A., Joseph S.B., Chen M., Castrillo A., Repa J., Wilpitz D., Mangelsdorf D., and Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell Biol. 23 (2003) 2182-2191